Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
Crossref DOI link: https://doi.org/10.1007/s00277-017-2973-2
Published Online: 2017-03-24
Published Print: 2017-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kaur, Varinder http://orcid.org/0000-0002-6480-7204
Swami, Arjun
Funding for this research was provided by:
Not applicable
License valid from 2017-03-24